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Kaposi’s sarcoma-associated herpesvirus (KSHV) or
human herpesvirus 8 has been established as the etio-
logical agent of Kaposi’s sarcoma and certain AIDS-as-
sociated lymphomas. KSHV establishes latent infection
in these tumors, invariably expressing high levels of the
viral latency-associated nuclear antigen (LANA) pro-
tein. LANA is necessary and sufficient to maintain the
KSHV episome. It also modulates viral and cellular tran-
scription and has been implicated directly in oncogene-
sis because of its ability to bind to the p53 and pRb
tumor suppressor proteins. Previously, we identified
the LANA promoter (LANAp) and showed that it was
positively regulated by LANA itself. Here, we present a
detailed mutational analysis and define cis-acting ele-
ments and trans-acting factors for the core LANAp. We
found that a downstream promoter element, TATA box,
and GC box/Sp1 site at 29 are all individually required
for activity. This architecture places LANAp into the
small and unusual group of eukaryotic promoters that
contain both the downstream promoter element and
TATA element but lack a defined initiation site. Further-
more, we demonstrate that LANA regulates its own pro-
moter via its C-terminal domain and does bind to a de-
fined site within the core promoter.
With the demonstration of herpesvirus-like DNA sequences in
Kaposi’s sarcoma (KS)1 biopsy samples but not other tissue (1)
and subsequent sequence analysis, Kaposi’s sarcoma-associated
herpesvirus (KSHV) or human herpesvirus 8 was uncovered as
an etiological agent of KS. Later, two lymphoproliferative disor-
ders, primary effusion lymphoma (PEL) and multicentric Castle-
man’s disease (1–4), were shown to also contain KSHV. Since
then, exhaustive epidemiological studies have confirmed the role
of KSHV in these cancers. KSHV is the first -2 herpesvirus
(rhadinovirus) to infect hominoids (5–7). Characteristically,
-herpesviruses, which also include lymphocryptoviruses such as
Epstein-Barr virus (EBV), infect lymphocytes (8, 9). Consistent
with this classification, KSHV establishes life-long latent infec-
tion in B cells (10–12), which eventually progress to lymphomas
in immunocompromised patients.
Like other herpesviruses, KSHV can enter two different life
cycles: lytic replication or latency. During lytic replication, all
viral proteins are expressed and viral particles are released
from the host cell, eventually resulting in the destruction of the
host cell. During latent infection, only a few viral genes are
expressed, and these are required for the establishment and
maintenance of latency (13–18). In KS, KSHV persists latently
in the majority of tumor cells, with fewer than 5% of cells
undergoing spontaneous lytic replication (19–22). All stages of
KS as well as multicentric Castleman’s disease and PEL, ex-
press high levels of the latent proteins, in particular the laten-
cy-associated nuclear antigen (LANA) (19, 23–25).
The LANA (open reading frame (ORF) 73, LNA) protein is
the predominant target of anti-KSHV antibodies in infected
individuals. Since KSHV does not encode an ORF with homol-
ogy to either EBV EBNA-1 or EBNA-2, it has been surmised
that KSHV LANA has subsumed the functions of the various
EBNA proteins. Although LANA shows no homology at the
sequence level, its phenotype and structural features are rem-
iniscent of the EBV EBNA-1 protein, such as an extended
central region of repeats. Like EBNA-1, LANA is localized to
the nucleus and associated with chromatin. Two nuclear local-
ization signals are located one each in the C-terminal region
and N-terminal region (26, 27). The C terminus of LANA is
required for dimerization (26) and DNA binding. LANA specif-
ically binds to two 17-bp motifs in the KSHV terminal repeats
(TR). This interaction is necessary and sufficient for latent
DNA replication (28–30). Chromatin binding is mediated pri-
marily by the N terminus of the protein and tethers the KSHV
episome to cellular chromosomes, thereby ensuring proper seg-
regation during host cell division (31–37). In addition to its role
in viral episome maintenance, LANA modulates host cell be-
havior to create a suitable environment for latent KSHV per-
sistence. LANA can cooperate with activated ras in fibroblast
transformation assays (38) and activates the human telomer-
ase promoter (39). Biochemical studies show that LANA binds
to p53, Rb (38, 40), and a growing number of cellular transcrip-
tion factors: Ring3, mSin3, ATF/CREB2, and CREB-binding
protein (41–44).
We and others have identified a cluster of three latently
expressed proteins (v-FLIP, v-cyclin, and LANA) and have
* The costs of publication of this article were defrayed in part by the
payment of page charges. This article must therefore be hereby marked
“advertisement” in accordance with 18 U.S.C. Section 1734 solely to
indicate this fact.
‡ Present address: Dana-Farber Cancer Institute, Harvard Univer-
sity, Boston, MA 02115.
¶ To whom correspondence should be addressed: University of Okla-
homa Health Sciences Center, Dept. of Microbiology and Immunology,
940 Stanton L. Young Blvd., Oklahoma City, OK 73104. Tel.: 405-271-
2133 (ext. 46645); Fax: 405-271-3117; E-mail: dirk-dittmer@ouhsc.edu.
1 The abbreviations used are: KS, Kaposi’s sarcoma; KSHV, Kaposi’s
sarcoma-associated herpesvirus; PEL, primary effusion lymphoma;
EBV, Epstein-Barr virus; LANA, latency-associated nuclear antigen;
ORF, open reading frame; TR, terminal repeat(s); CREB, cAMP-re-
sponse element-binding protein; LANAp, LANA promoter; DPE, down-
stream promoter element; UTR, untranslated region; aa, amino acid(s);
INR, initiator element.
THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 279, No. 16, Issue of April 16, pp. 16822–16831, 2004
© 2004 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in U.S.A.
This paper is available on line at http://www.jbc.org16822
This is an Open Access article under the CC BY license.
shown that these proteins were expressed by differentially
spliced, multicistronic mRNAs. The latent messages all were
regulated by the same cis-regulatory region, which is called the
LANA promoter (LANAp) (19, 45, 46). The cis-minimal regula-
tory region of LANA is sufficient for the high level LANAp
activity in cell lines of different origin: B cell-derived, endothe-
lium-derived, and epithelium-derived. We and others previ-
ously identified DNA fragments upstream of the LANA ORF,
which exhibited promoter activity in reporter-based assays (14,
19, 45). Fig. 1A summarizes the location of all LANA promoter
mutants reported previously or generated for this study and
summarizes their promoter activity in HEK293 cells. Similar
results were observed in SLK (a KS-derived endothelial cell
line) and B cell tumor lines (BJAB and BCBL-1). A set of
mutants (pGL3-1 to pGL3-5) were constructed by Sarid et al.
(14) and kindly provided to us by the authors. All constructs
exhibited basal activity independently of the presence of other
KSHV proteins. However, our studies also showed that LANAp
was regulated positively by LANA and negatively by the p53
tumor suppressor protein (47). Thus, so far these two are the
only known trans-acting factors that regulate LANAp. An anal-
ysis of the methylation status in the LANA promoter revealed
the complete absence of methylation in LANAp in PEL and KS
infection (48). This phenotype is consistent with the constitu-
tive transcriptional activity of LANAp and sets LANAp apart
from other KSHV promoters that are rapidly methylated and
silenced upon infection (48). In transgenic mice, LANAp was
active in CD19 B cells but not in CD3 T cells, demonstrating
that the cis-acting elements in LANAp are sufficient for appro-
priate lineage specificity (49) and that LANAp, in the absence
of other viral genes, is sufficient to drive latent gene
expression.
Here, we present a detailed mutational analysis of LANAp to
define cis-acting elements and trans-regulatory factors. We
demonstrate that LANA promoter activity depends on a down-
stream promoter element (DPE) and TATA box as well as
members of the Sp1/Krueppel family of transcription factors.
LANAp is the first viral promoter that is a member of the class
of eukaryotic promoters that contain both a DPE element and
a TATA element but lack a defined initiation site.
MATERIALS AND METHODS
Plasmids—All nucleotide sequence positions are based on the BC-1
KSHV isolate as sequenced by Russo et al. (82). Plasmids pDD41,
pDD83, pDD104, pDD124, pDD125, pDD163, pDD274, and pDD267
were described previously (47, 49). The plasmids pGL3–1 (pDD463),
pGL3–2 (pDD464), pGL3–3 (pDD465), pGL3–4 (pDD466), and pGL3–5
(pDD467) were a gift from Yuan Chang (University of Pittsburg, OH)
(14). These were originally PCR-amplified from the BC-1-derived KSHV
isolate, whereas all other plasmids in this paper were cloned from a
KS-derived KSHV -library (13). All plasmids were sequenced to con-
firm sequence and orientation and showed no deviation from the KSHV
sequence deposited by Russo et al. (82). The 5-UTR region up to the
NcoI site (nucleotides 127,296 to 127,609) in pDD124, pDD125, and
pDD168 was PCR-amplified from the BCBL-1 KSHV isolate. The NcoI/
NheI fragment of pDD83 was modified to blunt ends using DNA poly-
merase I, large (Klenow) fragment (New England BioLabs, Beverly,
MA). The blunted fragment was inserted into the SmaI site of pBlue-
script II KS (/) (Stratagene, La Jolla, CA) to yield pDD750. The
plasmids pDD751 and pDD753 were generated by inserting the SacI/
KpnI fragment of pDD750 into the SacI/KpnI sites of pGL3 basic (Pro-
mega, Madison, WI) and inserting the XhoI/SacI fragment of pDD750
into the XhoI/SacI sites of pGL3 basic, respectively. Plasmids express-
ing LANA mutants, LANA1 C50 (pDD770), LANA1 NLS DED
(pDD771), LANA1 NLS LZ-C (pDD772), and LANA1 1002–1062
(pDD774) (courtesy of Joonho Choe, Korea Advanced Institute of Sci-
ence and Technology, Korea), were described previously (70, 83). Plas-
mids with larger deletions of LANA, LANA-A (pDD720), LANA-AB
(pDD721), LANA-BC (pDD722), and LANA-C (pDD7230) were as de-
scribed by Garber et al. (29).
For the construction of the target plasmid for transposon mutagen-
esis, the NotI restriction site in pDD83 was destroyed by digestion with
NotI, Klenow-mediated fill in and blunt religation. This yielded
pDD365. pDD365 gives results identical to pDD83, confirming that
removal of the NotI site and vector sequences distal to the LANAp
insert had no effect on LANAp-dependent reporter gene transcription.
Afterward, transposon mutagenesis was performed on pDD365 using
the EZ::TN In-Frame Linker Insertion Kit (Epicenter Technologies).
This method relies on the ability of a modified 1000-bp Tn5 transposon
element-coupled to transposase to insert itself randomly into target
DNA in vitro (81, 84). Transposon events are identified by kanamycin
resistance. DNAs from positive clones were subsequently digested with
NotI to release the KanR marker and religated to regenerate a NotI site
and a 57-bp insertion in the clone. 400 mutants were randomly selected
for plasmid purification and analysis. Since the size of the LANAp
fragment is 552 bp compared with 2500 bp (pGL3 basic vector minus
origin and minus AmpR region), we expected one in five clones to
contain an insertion in the LANAp region. Unfortunately, of 400 Tn5
mutants, we isolated only 12 mutants with an insertion in the 552-bp
KSHV LANAp sequence. This is less than the expected ratio and sug-
gests integration bias on the part of the Tn5 in vitro transposon reac-
tion. Transposon insertions in plasmids pDD700–pDD711 were con-
firmed by sequencing. In order to screen the TN5 mutants, we
eliminated a NotI site in the vector backbone, yielding pDD365. PstI
linkers (New England BioLabs, Beverly, MA) were ligated into the
SmaI and PvuII sites of pDD83 to yield pDD461 and pDD413, respec-
tively. A map of all reporter constructs is shown in Fig. 1. For the
PCR-directed site mutagenesis, pDD83 served as the wild-type tem-
plate. Mutants containing two base pair substitutions in the putative
transcription factor binding sites of LANAp were generated using the
GeneTailorTM site-directed mutagenesis system (Invitrogen). The two
base pair substitutions in pDD780, pDD782, pDD783, and pDD784 are
shown in Fig. 2A and were confirmed by sequencing. To eliminate the
possibility that inadvertent second-site mutations in the luciferase ORF
might be responsible for the loss of luciferase activity, we recloned the
LANAp region containing 2-bp substitutions that result in loss of func-
tion into pGL3 basic. The “recloned” plasmids showed similar promoter
activity compared with the parent plasmids, demonstrating that loss of
function was due to the internal mutation (data not shown).
Tissue Culture and Transfection—HEK293 cells were cultured in
Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bo-
vine serum, 2 mM L-glutamine, penicillin (0.05 g/ml), and streptomycin
(5 units/ml) (all from Invitrogen) at 37 °C under 5% CO2. At day 1, cells
were seeded at 5  104 cells/ml/well (6-well plate) to reach 50% conflu-
ence after 24 h. At day 2, 4000 ng of total DNA together with 1000 ng
pDD173 (pCDNA3.1-hislacZ; Invitrogen) was suspended in 150 l of
Dulbecco’s modified Eagle’s medium (no serum, no antibiotics) and 7.5
l of Superfect (Qiagen, Valencia, CA). The transfection mixture was
incubated for 30 min at room temperature, and the total volume was
adjusted to 1.5 ml with complete medium. Cells were washed once with
Dulbecco’s modified Eagle’s medium, and 0.5 ml of transfection mixture
was added per triplicate well. Cells were incubated overnight at 37 °C
under 5% CO2, and the medium was exchanged with complete medium.
All transfections were repeated at least three times each in triplicate.
Luciferase Activity—Firefly luciferase activity was measured 48 h after
transfection using the Dual-Luciferase reporter assay system (Promega)
in a Turner TD20/20 luminometer according to the manufacturer’s in-
structions. -Galactosidase activity was determined using o-nitrophenyl-
-D-galactopyranoside as described (47) or the Galacto-Light Plus kit
(Tropix, Bedford, MA) according to the manufacturer’s recommendations.
Electrophoretic Mobility Shift Assay—Nuclear extracts were pre-
pared from BCBL-1 cells and diluted with dilution buffer at 1:1 ratio (12
mM HEPES (pH 7.5), 50 mM KCl, 6 mM MgCl2, 5 M ZnSO4, 2 mM
dithiothreitol, 0.1% Nonidet P-40, and 50% glycerol). Annealed double-
stranded oligonucleotides (50 ng) were end-labeled with [-32P]ATP
using T4 polynucleotide kinase. The binding reaction was performed at
room temperature for 30 min in a mixture containing 2 l of the diluted
nuclear extract (10 g), 1 g of poly(dI-dC), 2 l of 1 M NaCl, 3 l of
5 binding buffer (5 mM MgCl2, 2.5 mM EDTA, 2.5 mM dithiothreitol,
250 mM NaCl, 50 mM Tris-HCl (pH 7.5), and 20% glycerol), and 2 l of
labeled oligonucleotide. For the competition experiments, unlabeled
double-stranded oligonucleotides were added in up to a 100-fold molar
excess in the initial reaction mixture. For supershift analysis, after the
incubation for 10 min at room temperature, 3 l of a polyclonal rabbit
antibody against LANA (a gift from Jae U. Jung, Harvard University)
or a polyclonal goat anti-Sp1 (Santa Cruz Biotechnology, Inc., Santa
Cruz, CA) was added to the binding reaction mixture. DNA-protein
complexes were analyzed by electrophoresis through 4.7% polyacryl-
amide gel at 200 V at 4 °C for 2 h.
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Western Blot Analysis—HEK293 cells were transfected with 10 g of
total DNA using 20 l of Superfect (Qiagen, Valencia, CA) per 10-cm
dish. 48 h after the transfection, whole cell extracts were prepared in
300 l of sample buffer (80 mM Tris, pH 6.8, 100 mM dithiothreitol, 2%
SDS, 10% sucrose, and 0.004% bromphenol blue) with boiling for 5 min.
Lysates were electrophoretically separated on Bio-Rad 4–15% gradient-
FIG. 1. Mutational analysis of
LANAp. A, summary of reporter plas-
mids with deletion mutants in LANAp.
10 or 0, relative promoter activity is
higher than 10-fold, or less than 10-fold
compared with the basal promoter activ-
ity of control vector (pGL3 basic). B, dia-
gram of the reporter plasmids used in
transient transfection assay to investi-
gate the contribution of sequences down-
stream of 1 transcriptional initiation
site to LANAp activity. MCS, multiple
cloning site. C, promoter activity of muta-
tions in LANAp, which affect sequences
downstream of the start site. HEK293
cells were transfected with the indicated
plasmids. Data represent the mean rela-
tive luciferase activity after 48 h of trip-
licate experiments normalized by co-
transfected -galactosidase activity. S.D.
is indicated by error bars. D, analysis of
transposon-generated insertion mutants
in LANAp. HEK293 cells were trans-
fected with the indicated plasmids repre-
senting insertion mutants in LANAp.
Each insertion site is indicated relative to
the transcriptional initiation site (127,880
as 1). Bars represent the mean relative
luciferase activity in triplicate experi-
ments. Transfection efficiency was nor-
malized by co-transfected -galactosidase
activity. S.D. is indicated by error bars.
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ready gels. Proteins were transferred to Hybond™-P membranes (Am-
ersham Biosciences) in transfer buffer (25 mM Tris-HCl, pH 8.3, 12 mM
glycine, and 10% methanol), and the membranes were blocked with 5%
milk overnight at 4 °C. The membranes were washed three times with
phosphate-buffered saline (0.05% Tween 20) for 10 min each time. The
membranes were incubated with a polyclonal rabbit antibody (1:5000
dilution) against LANA (a gift from Jae U. Jung) in Blotto HD (28 mM
Tris-HCl, 22 mM Tris base, 1.4 mM CaCl2, 80 mM NaCl, 2% Nonidet
P-40, and 0.2% SDS) containing 0.2% bovine serum albumin for 1 h and
then washed three times with Blotto HD (0.2% bovine serum albumin).
The blots were incubated with horseradish peroxidase-conjugated sec-
ondary antibody against rabbit IgG (1:5000 dilution; Santa Cruz Bio-
technology) in Blotto HD (0.2% bovine serum albumin) for 45 min and
subsequently washed three times with Blotto HD. After final washing
with phosphate-buffered saline for 10 min, the blots were developed
with the Western blotting detection system (Amersham Biosciences).
RESULTS
Sequences Downstream of the Transcription Start Site Con-
tribute to Core Promoter Activity—The side-by-side comparison
of the deletion clones from Sarid et al. (14) with those from
Jeong et al. (47) allowed us to further define LANAp. Confirm-
ing previous observations, both sets of clones exhibited signif-
icant constitutive promoter activity as long as sequences up to
88 (127,968) were included. However, the deletion clones
starting at 11 (127,869) showed a generally lower level of
activity compared with the clones starting at 271 (127,609).
Of the two deletion mutants that extended to 279 (128,159)
and differed only by their proximal site at 271 (127,609) or
11 (127,869), the clone starting at 271 exhibited 10-fold
promoter activity, whereas the clone starting at 11 exhibited
only 3-fold promoter activity above vector control (Fig. 1A).
A second difference between the 271 to 279 reporter
construct (pDD83) and the 11 to 279 reporter construct
(pGL33) was that in the latter the KSHV promoter region
was cloned into the multiple cloning site of pGL3basic (Pro-
mega), whereas pDD83 starts at the luciferase start codon and
replaces the 5-UTR and translation-initiation sequence origi-
nally present in pGL3 basic with KSHV sequences (Fig. 1B). To
investigate the influence of this difference, we cloned the region
271 to 279 into the multiple cloning sites of pGL3 basic as
shown in Fig. 1B. This yielded pDD753 retained the 5-UTR of
pGL3basic and differed from pGL3-3 by 291 nucleotides down-
stream of LANA promoter start site. As shown in Fig. 1D,
transfection assays in HEK293 cells with pDD465 (pGL3-3)
and pDD753 showed significant differences in promoter activ-
ity, demonstrating that sequences between 11 and 271 con-
tribute to LANAp activity. Similar results were obtained in the
KS-derived SLK, the B cell-derived BJAB and the PEL-derived
BCBL-1 cell lines (data not shown).
Transposon-mediated Insertion Mutagenesis—To identify
additional cis-acting elements in the LANAp region, we sub-
jected our reporter plasmid pDD365 (271 to 279) to in vitro
transposon mutagenesis using the EZ::TN in-frame linker in-
sertion kit (Epicenter Technologies). Fig. 1D shows the relative
reporter activity of each insertion mutant in HEK293 cells.
Mutants pDD700 (270), pDD701 (249), pDD702 (245),
pDD703 (241), pDD704 (241), pDD705 (237), pDD707
(200), pDD709 (198), pDD710 (179), and pDD711 (44)
show decreased promoter activities compared with the wild-
type control, pDD83. In contrast, mutants pDD706 and
pDD708 show promoter activities higher than the wild-type
FIG. 2. Analysis of minimal cis-acting elements in LANAp. A,
site-directed mutagenesis of putative transcription factors binding
sites. 2-bp mutations were introduced into the TATA box and the two
putative Sp1 binding sites. Two PstI linker insertion mutations (9 and
28) and one transposon-mediated insertion mutation (46) were also
introduced in cis-minimal regulatory region of LANAp. B, luciferase
activity in HEK293 cells after transfection with the indicated plasmids.
C, luciferase activity in SLK cells after transfection with the indicated
plasmids. D, luciferase activity in BCBL-1 cells after transfection with
the indicated plasmids. E, luciferase activity in BC-3 cells after trans-
fection with the indicated plasmids. F, luciferase activity in BJAB cells
after transfection with the indicated plasmids. Data represent the
mean -fold induction after 48 h of triplicate experiments. 1, transcrip-
tional initiation site of LANAp; *, alternative transcriptional initiation
site mapped by Sarid et al. (14). S.E. is indicated by error bars.
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control, suggesting that the transposons did not disrupt an
essential site. We also investigated whether any of these inser-
tion mutants had lost the ability to be transactivated by LANA
(data not shown). None of them did, suggesting that LANA’s
transactivation of LANAp uses other sites in the promoter.
Based on our deletion analysis, we conclude that essential
LANAp elements are located between 11 and 271 but not
distal to 88 relative to the transcription start site. The loss-
of-function transposon mutant at 43 prompted us to investi-
gate the core LANA promoter in detail.
Core Promoter Function Depends on TATA Box, DPE, and
Sp1 Elements—To investigate specific transcriptional factors
that would be important for core LANAp activity, we intro-
duced targeted mutations into predicted cis-acting elements in
the LANAp (pDD83). Fig. 2A shows a detailed sequence anal-
ysis and insertion mutagenesis. In general, eukaryotic promot-
ers are considered either TATA-containing or TATA-less. In
TATA-containing promoters, the TATA box is located 30 nu-
cleotides upstream of the transcription initiation site (50, 51).
The LANA promoter did not contain a TATA box consensus site
30 bp upstream of the latent LANA mRNA start site (indicated
by 1 in Fig. 2A) as previously determined (19). TATA-less
promoters invariably contain a DPE located at about 30 nucle-
otides downstream of the transcription initiation site. The DPE
consensus sequence is 5-(A/G)G(A/T)(C/T)(G/A/C) (52). We
identified such a sequence in the LANA promoter at position
32 (127,848) (i.e. within the required distance of the LANA
start site at 127,880). Alternatively, Sarid et al. (14) identified
additional, distal transcription initiator sites at 19 (127,899,
indicated by a star in Fig. 2A) and 69 (127,949) relative to the
start site at 1. The transcription initiation site at 19 is
located 34 bp downstream of a TATA consensus motif. There-
fore, we investigated two hypotheses. (a) Is the DPE required
for LANAp activity and/or (b) is the TATA element required for
LANAp activity?
The activity of DPE-containing promoters is dramatically
decreased if the exact spacing between the DPE and the tran-
scription initiation site is altered (50). To examine the possi-
bility that LANAp was dependent on the DPE, we introduced a
6-bp PstI linker insertion between the DPE and the transcrip-
tion initiation site (pDD413). As shown in Fig. 2, B–E, this
insertion mutation completely abrogated LANAp activity in
every cell line tested. To determine the importance of the DPE
directly, we introduced a targeted mutation (CG to AT) into the
DPE element (pDD788). This point mutation also destroyed
LANAp activity (Fig. 2, B–E), which demonstrates that LANAp
activity was dependent on the DPE.
To examine the possibility that LANAp activity was depend-
ent on the TATA box, we performed mutagenesis of the TATA
box. Mutation (TA to GC) of the putative TATA box abolished
LANAp activity (pDD784 in Fig. 2, B–E). A 6-bp linker inser-
FIG. 3. Mapping of LANA transactivation domain. A, a sche-
matic diagram of LANA expression vectors containing different LANA
deletion mutants as described by Lim et al. (42). B, luciferase activity in
HEK293 after transfection with the indicated LANA expression vectors
or with an empty expression vector together with a reporter plasmid
containing LANAp. C, Western blot analysis of LANA protein expres-
sion. HEK293 cells were transfected with 10 g of total DNA/10-cm
dish. Whole cell extracts, prepared 48 h after the transfection, were
electrophoretically separated on 4–15% gradient SDS-PAGE gel. The
expression of LANA mutants was detected using a polyclonal rabbit
antibody (1:5000 dilution) against LANA. The wild type (WT) LANA in
pDD105 contains shorter acid repeats in the central domain with a total
length of 1003 aa, whereas the other mutants are constructed from wild
type LANA containing longer repeats with a total length of 1162 aa. D,
luciferase activity in HEK293 cells after transfection with the indicated
LANA expression vectors or with an empty expression vector together
with a reporter plasmid containing seven copies of the entire KSHV TR
sequence in the pGL3 promoter. Bars represent the mean relative
luciferase activity after 48 h of triplicate experiments, and transfection
efficiency was normalized by co-transfected -galactosidase activity.
S.D. is indicated with error bars.
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tion (pDD461) between 1 and the putative TATA box also
abolished activity. A larger 57-bp transposon insertion
(pDD711) between the start site and putative TATA box totally
demolished LANAp activity, suggesting that the TATA box is
also required for LANAp activity. These data strongly suggest
that the activity of LANAp was simultaneously dependent on a
TATA box as well as DPE.
Sequence analysis revealed two putative GC box/Sp1 binding
sites at positions 29 and 46 in LANAp. To examine the
contribution of these sites to LANAp activity, we introduced
2-bp substitution mutations into the sites. As shown in Fig. 2,
B–E, the mutation introduced into the first GC box/Sp1 binding
site (Sp1.B at 29 and 30) completely abrogated LANAp
activity (pDD780), whereas two independent mutations in the
second GC box/Sp1 binding site (Sp1.C at 46 and 47 or at
50 and 51) reduced the promoter activity by 50% (pDD782
and pDD783). These data demonstrate that the GC box/Sp1
site at 29 was essential for LANAp activity, whereas the GC
box/Sp1 site at position 46 augmented promoter activity. In
summary, we identified three cis-acting elements (TATA, DPE,
and GC box/Sp1) within the core LANAp that were independ-
ently required for activity.
Autoregulation of the LANAp by LANA Protein—We previ-
ously reported that LANA transactivates its own promoter
(47, 53) but had been unable to demonstrate full-length
LANA binding to the LANAp 271 to 279 fragment directly
(29). This may have been due to technical difficulties of
LANA-based electrophoretic mobility shift assay, but it left
open the alternative possibility that LANA, like adenovirus
E1A or EBV EBNA-2, regulated transcription via protein-
protein interactions and did not contact DNA directly (54,
55). To map the domain of LANA that was required to acti-
vate LANAp, we transfected different deletion mutants of the
LANA protein together with a reporter plasmid containing
the LANAp (Fig. 3A). As depicted in Fig. 3B, two mutants,
each containing different C-terminal deletions, both lost their
ability to transactivate the LANAp. In contrast, mutants that
contain central domain deletions but retain their intact C-
terminal domain transactivated the LANAp similarly to wild-
type LANA. These data suggest that the central domain of
LANA is dispensable for the transactivation of its own pro-
moter. We obtained essentially similar data using a second
set of mutants (29) with larger deletions of the central do-
main (data not shown).
To confirm expression of these mutants, we performed West-
ern blot analysis using polyclonal rabbit antiserum against
LANA (Fig. 3C). All mutants were expressed upon transient
transfection and migrated at the expected size. The wild type
LANA in pDD105 contained shorter repeats in central domain
FIG. 4. DNA binding activities for
the essential GC box/Sp1 site in
LANAp. Nuclear extracts were prepared
from BCBL-1 cells. Gel shift assay with
32P-labeled oligonucleotide containing a
consensus Sp1 binding site (5-CCCTTG-
GTGGGGGCGGGGCCTAAGCTGCG-3).
Competition experiments were performed
by the addition of increasing concentrat-
ions of unlabeled DNA oligonucleotides,
as indicated above the gel, and gel shift
assay with 32P-labeled LANAp oligonu-
cleotide containing the second putative
Sp1-binding-site (5-ATTGTCCCGGGCG-
CCGCGTAG-3). DNA-protein complexes
are labeled with the letters A–G on the
right. P, free probe. The first lane is probe
only.
FIG. 5. Purified LANA C terminus binds to LANAp. Nuclear
extracts were prepared from BCBL-1 cells. A, gel shift assay with
32P-labeled LANAp oligonucleotide (5-ATTGTCCCGGGCGCCGCG-
TAG-3). Lane 1, probe only; lane 2, probe with BCBl-1 nuclear extract;
lane 3, probe with BCBL-1 nuclear extract and excess cold probe; lane
4, probe with BCBL-1 nuclear extract and excess NF-B probe; lane 5,
probe with purified human Sp1 protein; lane 6, probe with purified
LANA C terminus protein. B, gel shift assay with 32P-labeled Sp1
oligonucleotide (5-CCCTTGGTGGGGGCGGGGCCTAAGCTGCG-3).
Lane 1, probe only; lane 2, probe with BCBl-1 nuclear extract; lane 3,
probe with BCBL-1 nuclear extract and excess cold probe; lane 4, probe
with BCBL-1 nuclear extract and excess NF-B probe; lane 5, probe
with purified human Sp1 protein; lane 6, probe with purified LANA C
terminus protein.
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with a total length of 1003 aa, whereas the other mutants were
constructed from wild type LANA containing longer repeats
with a total length of 1162 aa.
To confirm the functionality of the LANA mutants with
regard to their known TR-specific DNA binding, we transfected
the different LANA expression plasmids together with a re-
porter plasmid containing seven copies of the LANA binding
site in the KSHV TR region downstream of a minimal SV40
promoter. Previously, Garber et al. (28) showed that purified
LANA protein bound directly to the TR element and that in the
context of this reporter construct, LANA binding resulted in
strong transcriptional suppression of the adjacent heterologous
SV40 promoter. As shown in Fig. 3D, plasmids expressing the
intact C-terminal region of LANA showed the transcriptional
suppression comparable with wild-type LANA, whereas the
two C-terminal LANA mutants did not. This demonstrates that
all LANA mutants were expressed, that all were capable of
binding to the high affinity TR LANA binding site, and that the
central domain was dispensable for LANA’s transcriptional
activation activity on LANAp.
LANA Protein Binds to an Essential GC Box/Sp1 Motif in Its
Own Promoter—To investigate the binding of cellular tran-
scription factors to the essential GC box/Sp1 binding site at
29 of the LANAp, we performed an electrophoretic mobility
shift assay. Seven protein-DNA complexes (complexes a, b, c, d,
e, and f) were observed in BCBL-1 cells using an oligonucleo-
tide containing the predicted GC box/Sp1 binding site (29) in
LANAp (Fig. 4). Increasing amounts of the unlabeled probe
diminished the complexes in a dose-dependent fashion. Since
complexes a and b changed size upon competition, they proba-
bly represent multimeric complexes (Fig. 4, lanes 2–4). A 100-
fold molar excess of an unrelated sequence (NF-B) did not
compete for binding (Fig. 4, lane 5). Competition experiments
with increased amounts of an unlabeled Sp1 consensus oligo-
nucleotide did not compete these complexes (Fig. 4, lanes 6–8).
The addition of anti-LANA antiserum yielded a supershifted
band (Fig. 4, lane 9), indicating that some of these complexes
contained LANA. As a positive control, a Sp1 consensus oligo-
nucleotide was incubated with BCBl-1 extract (Fig. 4, lanes
10–19). Here, increasing amounts of the unlabeled Sp1 binding
site diminished the complexes in a dose-dependent fashion
(Fig. 4, lanes 15–17). Increasing amounts of unlabeled LANAp
oligonucletide competed for some of the lower migrating com-
plexes but not the main Sp1 complex (Fig. 4, lanes 11–13),
consistent with the limited sequence similarity of both sites. A
100-fold molar excess of an unrelated sequence (NF-B) did not
compete with any complex (Fig. 4, lane 14). The addition of
anti-LANA antiserum did not change the banding pattern (Fig.
4, lane 18), but the addition of an anti-Sp1 specific antiserum
did (Fig. 4, lane 19).
The LANA binding motif in the TR is a 20-bp GC-rich im-
perfect palindrome (5-ccccatgcccgggcgggagg) (29, 35), which
also fits a minimal GC box/Sp1 consensus sequence 5-GG(C/
A)G. Hence, we tested whether a highly purified LANA C-
terminal fragment that was known to bind to the TR (28, 29)
was able to bind the GC box/Sp1 element in LANAp. Shown in
Fig. 5 is an electrophoretic mobility shift assay using as probe
either the GC box/Sp1 element in LANAp (LANAp) or a con-
sensus Sp1 element (Sp1). The same multiple complexes as in
Fig. 4 were visible in BCBL-1 extracts (Fig. 5, lane 2 in both
panels). They were competed by a 100-fold excess of unlabeled
probe (Fig. 5, lane 3 in both panels), but not a 100-fold excess of
an irrelevant NF-B probe (Fig. 5, lane 4 in both panels).
Purified LANA C terminus shifts LANAp (Fig. 5A, lane 6) but
not Sp1 probe (Fig. 5B, lane 6). In contrast, purified human Sp1
shifted a Sp1 consensus probe (Fig. 5B, lane 5) but not the
FIG. 6. Cross-competition between the LANA binding site in
the TR and in the LANAp. Nuclear extracts were prepared from
BCBL-1 cells. A, gel shift assay with 32P-labeled LANAp oligonucleo-
tide. Lane 1, probe only; lane 2, probe with BCBl-1 nuclear extract;
lanes 3–5, probe with BCBL-1 nuclear extract and decreasing amounts
of unlabeled LANAp probe; lanes 6–8, probe with BCBL-1 nuclear
extract and decreasing amounts of unlabeled NF-B probe; lanes 9–11,
probe with BCBL-1 nuclear extract and decreasing amounts of unla-
beled TR probe; lanes 12–14, probe with BCBL-1 nuclear extract and
decreasing amounts of unlabeled Sp1 probe. B, gel shift assay with
32P-labeled TR oligonucleotide. Lane 1, probe only; lane 2, probe with
BCBl-1 nuclear extract; lanes 3–5, probe with BCBL-1 nuclear extract
and decreasing amounts of unlabeled LANAp probe; lanes 6–8, probe
with BCBL-1 nuclear extract and decreasing amounts of unlabeled
NF-B probe; lanes 9–11, probe with BCBL-1 nuclear extract and
decreasing amounts of unlabeled TR probe; lanes 12–14, probe with
BCBL-1 nuclear extract and decreasing amounts of unlabeled Sp1
probe. C, gel shift assay with 32P-labeled Sp1 oligonucleotide, Lane 1,
probe only; lane 2, probe with BCBl-1 nuclear extract; lanes 3–5, probe
with BCBL-1 nuclear extract and decreasing amounts of unlabeled
LANAp probe; lanes 6–8, probe with BCBL-1 nuclear extract and
decreasing amounts of unlabeled NF-B probe; lanes 9–11, probe with
BCBL-1 nuclear extract and decreasing amounts of unlabeled TR probe;
lanes 12–14, probe with BCBL-1 nuclear extract and decreasing
amounts of unlabeled Sp1 probe.
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LANAp probe (Fig. 5A, lanes 5). This demonstrates that LANA
protein can bind to an essential GC box/Sp1 binding site in its
own promoter but not a consensus Sp1 site and that the pre-
dicted GC box/Sp1 in the LANAp does not bind purified human
Sp1. Whether this site can bind other Sp1/Krueppel family
members is currently under investigation.
To test the relative affinities of the three related sites
LANAp (5-ATTGTCCCGGGCGCCGCGTAG), TR (5-CCCCA-
TGCCCGGGCGGGAGG), and consensus Sp1 (5-CCCTTGGT-
GGGGGCGGGGCCTAAGCTGCG) directly, we performed
cross-competition experiments in BCBl-1 extracts. Equal
amounts of LANAp, NF-B, TR, and Sp1 probe were used to
compete a labeled LANAp probe (Fig. 6A) or a TR probe (Fig.
6B) or a Sp1 probe (Fig. 6C). The LANAp site did not compete
efficiently with the TR site (Fig. 6B), whereas the TR site
competed efficiently with itself and with the LANAp site (Fig.
6A), suggesting that the TR site had a higher affinity for DNA
binding activities in BCBL-1 sites than the LANAp. An unre-
lated probe (NF-B) did not compete with any of the three
probes. An Sp1 consensus oligonucleotide did not compete with
either the LANAp or TR sites (Fig. 6C), reemphasizing that in
BCBL-1 cells under the binding conditions used here these
sites were different.
KSHV ORF 50/Rta Inhibits LANAp—As an immediate early
lytic gene product, KSHV ORF 50/Rta plays a critical role in
the induction of the viral lytic promoters (56–61). The ORF
50/Rta also transactivated the promoter of vGPCR/ORF 74,
which partially overlaps with the LANA 5-UTR (47, 62). This
close proximity suggested the hypothesis that ORF 50 was
involved in regulating the LANAp. Since LANA (and LANA-2)
are the only KSHV mRNAs that are not induced in response to
TPA or ORF 50/Rta (15),2 we hypothesized that perhaps ORF
50/Rta inhibited the LANAp directly. To test this hypothesis,
we transfected an ORF 50/Rta expression vector or an empty
expression vector together with reporter plasmids containing
different deletion mutants of the LANAp into HEK293 cells. As
shown in Fig. 7A, ORF 50/Rta expression reduced LANAp
activity to as little as 12% of vector control. Repression by ORF
50/Rta did not map to any particular cis-regulatory region of
the promoter, suggesting that ORF 50/Rta squelched the LANA
promoter by competing for cellular factors. Fig. 7B confirmed
ORF 50/Rta protein expression and functionality by testing its
transactivation ability on the ORF 74/vGPCRp, as previously
defined (47).
DISCUSSION
The results of side-by-side transient transfection studies
comparing the deletion clones from Sarid et al. (14) with those
from Jeong et al. (47) demonstrated that important regulatory
elements in LANAp are present downstream of the mRNA
start site (Fig. 1A). The comparison of isogenic reporter plas-
mids differing only by the presence or absence of 260 bp within
the LANA 5-UTR revealed significant differences in promoter
activity. This implied that sequences between 11 and 271
contribute to LANAp activity (Fig. 1D). We found at least one
essential promoter element, the DPE, to be located in this
region.
Generally eukaryotic promoters are composed of DNA se-
quences that direct accurate transcriptional initiation by the
RNA polymerase II complex (63, 64). One or all of these se-
quence motifs can be recognized in most eukaryotic promoters:
the TATA box, the initiator element (INR), and the DPE. In
TATA-dependent promoters, both the TATA box, typically lo-
cated about 30 bp upstream of the transcriptional initiation
site and bound by the TATA-binding protein subunit of TFIID,
and the INR are used to accurately position the basal transcrip-
tion machinery, leading to a single defined mRNA initiation
site (50, 65). In TATA-less promoters, the DPE in conjunction
with the INR is used for the same purpose (50, 65). The DPE is
typically located 28–32 bp downstream of the transcriptional
2 Damania, B., Jeong, J. H., Bowser, B. S., DeWire, S. M., Staudt,
M. R., and Dittmer, D. P. (2004) J. Virol., in press.
FIG. 7. Inhibition of the LANAp by ORF 50. A, luciferase activity in HEK293 after cotransfection with an ORF 50 expression vector or an
empty expression vector together with reporter plasmids containing different LANAp regions. 279 RS, a reporter plasmid (pDD465 in Fig. 1)
containing LANAp region between 20 and 279. B, luciferase activity in HEK293 cells after cotransfection with an ORF 50 expression vector or
an empty expression vector together with a reporter plasmid containing vGPCR promoter (pDD163). vGPCR, viral G protein-coupled receptors.
Bars represent the mean relative luciferase activity after 48 h of triplicate experiments. The -fold promoter activity with the expression of ORF
50 relative to the promoter activity without ORF 50 expression is indicated (A and B).
FIG. 8. Model for the regulation of the minimal regulatory
region of LANAp based on Kutach et al. (65). Pol II, polymerase II;
TBP, TATA-binding protein.
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initiation site, and the precise spacing between DPE and the
INR is critical for the cooperative binding of holo-TFIID to a
TATA-less core promoter (50, 63). Consistent with this notion,
it has been shown that TAFII60 and TAFII40 of TFIID interact
with the DPE to stabilize the transcription initiation complex
(50). So far, all known DPE-containing promoters are TATA-
less, and all TATA-containing promoters are DPE-less, al-
though most experimental data are derived from Drosophila
promoters. The INRs encompassing the transcription initiation
site can be found in TATA-dependent and TATA-independent
promoters, and TFIID has been found to contact the INR
through its TAFII150 and TAFII250 subunits (66).
The LANAp is different in its core architecture. LANAp does
not contain a recognizable INR, which is consistent with the
multiple start sites that we and others previously described
(19, 46). We found that by mutational analysis, both DPE and
TATA box elements were independently required for LANAp
function (Fig. 2). This arrangement is rarely found in eukary-
otic promoters and is in contrast to the latent EBV EBNA Qp
promoter (67, 68), which is TATA-independent. By sequence
analysis, only 14% of eukaryotic promoters contain both a DPE
and TATA box, whereas 31% contain neither and 55% contain
one or the other (65). Understanding LANAp, in addition to
understanding KSHV latency, will yield general insights into
the mechanism and significance of this unique group of pro-
moters for which no other experimental model currently exists.
We propose the arrangement shown in Fig. 8 to accommo-
date the results of our mutational analyses. Point mutants in
the TATA, the DPE, or GC box/Sp1 sites independently abol-
ished promoter activity. In the case of LANAp, the TATA box
and DPE alone or in conjunction is not sufficient to stabilize the
basal transcription machinery because of the aberrant spacing.
In the LANAp, the distance between the DPE and TATA box is
90 bp (as opposed to the 30-bp distance between TATA and
INR or DPE and INR that has been demonstrated for other
promoters). We surmise that this would prevent appropriate
interactions between these cis-acting elements and their cog-
nate DNA binding subunits in TFIID and that a third DNA
contact, in our case through a GC box/Sp1 site, is required to
ensure proper spacing and transcription initiation. Since we
have been unable to demonstrate direct binding of Sp1 (Fig. 5)
and Sp3 (data not shown) to LANAp, we surmise that other
Sp1/Krueppel family members supply this function and that in
BCBL-1 cells, LANA itself is part of this complex (Fig. 4).
We found that LANA transactivated LANAp through aa
751–1161, which contains the putative leucine zipper and DNA
binding region. By contrast, the central region containing the
repeats was not required for LANAp transactivation (Fig. 4).
The requirements for autoactivation of LANAp differ from the
requirements for activation of the EBV LMP-1 promoter, since
Groves et al. (69) showed that a LANA mutant containing
amino acids 267–971 but lacking the C-terminal region was
able to activate this promoter (69). At this point, we do not
know which domains within the C-terminal DNA binding do-
main are required for LANAp transactivation. We cannot ex-
clude the possibility that more than one domain of LANA may
be needed for transactivation, since, for instance, Lim et al. (70)
previously demonstrated that the N-terminal 90 amino acids
were required for the C-terminal region-mediated DNA binding
and dimerization function of LANA (70). In addition, amino
acids 1129–1143 were shown to be required for the transacti-
vation of the EBV Cp by LANA (71). Clearly, there are multiple
mechanisms through which LANA can regulate target promot-
ers, and these involve multiple regions of the LANA protein.
Since KSHV latent persistence is dependent on LANA protein
and LANA protein positively regulates its own expression,
studies of this feedback circuitry such as presented here may
identify novel targets for antiviral drugs, with the potential to
clear latent infection.
LANAp overlaps with a lytic gene promoter, K14/vGCR (ORF
74) promoter, which is transactivated by an immediate early
lytic gene product, ORF 50/Rta. The ORF 50/Rta transactivator
interacts with many host cellular transcription regulators,
such as CCAAT/enhancer-binding protein  (72, 73), Sp1 (74),
octamer-binding protein (Oct-1) (75), STAT3 (76), CREB-bind-
ing protein (77), SWI/SNF (78), TRAP/Mediator (78), MGC
2663 (79), and p53 (80). Hence, we set out to test the hypothesis
that ORF 50/Rta can repress LANAp. Such an interaction
would explain why LANAp is not induced upon KSHV reacti-
vation (47). As shown in Fig. 6, Rta/ORF 50 repressed LANAp
activity up to 10-fold. Because we could not localize a defined
site through which this repression was mediated, we suggest
that ORF 50 squelches LANAp core activity through protein-
protein interactions.
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